Back to Results

Baxter International Inc (BAX)

Featured in High-Beta Stocks

Baxter International Inc. is a healthcare company listed on the NYSE as common stock under the ticker BAX. Through its subsidiaries, it develops and supplies a broad range of products used in medical care. Its operations are organized into three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. The company’s portfolio includes IV solutions, infusion systems, parenteral nutrition therapies, injectable and inhaled medicines, surgical hemostats and sealants, operating room technologies, patient monitoring and diagnostic equipment, and respiratory care devices. Baxter also provides drug compounding services and specialty pharmaceuticals. Its products are used in hospitals, dialysis centers, rehabilitation facilities, nursing homes, ambulatory surgery centers, doctors’ offices, and home-care settings under physician supervision. Founded in 1931, Baxter is headquartered in Deerfield, Illinois, and sells through direct, distributor, wholesaler, and specialty pharmacy channels across North America, Europe, the Middle East, Africa, Latin America, and Asia-Pacific.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-BAX
$26.49
20.1% Upside
Undervalued
$21.95
-0.5% Downside
Fair
Good
—
—
0.04
0.2%
July 30, 2026
-11.6x
1.9x
1.0x
11.398 B
19.031 B
46.0%
99.5%
4.0
-24.2%
-73.7%
Valuation • Fair Value

Baxter International Inc (NYSE-BAX) Fair Value by Valuation Model

Compare the primary fair value estimate for Baxter International Inc (NYSE-BAX) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$26.49

Estimated upside of 20.1% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$31.63

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

$9.50

Dividend discount model valuation reference.

EPV Fair Value

$11.95

Earnings power value estimate.

Comps Fair Value

$26.61

Comparable-company valuation reference.

Analyst Price Target

$21.95

Analysts imply downside of 0.5%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Baxter International Inc (NYSE-BAX) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Baxter International Inc (NYSE-BAX)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

11.32 B

Current operating scale indicator.

Revenue Forecast

11.354 B

Forward revenue estimate.

EBITDA

1.909 B

Current operating profitability reference.

EBITDA Forecast

1.98 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Baxter International Inc (NYSE-BAX) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Baxter International Inc (NYSE-BAX)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Good

Positive financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

-2.92

No elevated caution signal from this screen.

Altman Z-Score

4.0

Relatively strong balance-sheet zone.

FCF / Net Income

-73.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Baxter International Inc (NYSE-BAX). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Baxter International Inc (NYSE-BAX)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

July 30, 2026

Days to Earnings

9

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.2%

Income yield reference.

Upcoming Dividend

0.04

Upcoming distribution amount.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

USD

Currency used for the distribution.

Payout Ratio

-24.2%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Baxter International Inc (NYSE-BAX), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Baxter International Inc (NYSE-BAX) Stock Forecast & Technical Outlook

Review Baxter International Inc (NYSE-BAX) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Baxter International Inc (NYSE-BAX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Baxter International Inc (NYSE-BAX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Baxter International Inc (NYSE-BAX) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Baxter International Inc (NYSE-BAX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Baxter International Inc (NYSE-BAX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Baxter International Inc (NYSE-BAX)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Baxter International Inc (NYSE-BAX) has a Hold consensus, with 2 buy, 10 hold and 1 sell recommendations in the current data set.

Buy 2
Hold 10
Sell 1
FAQ • Fast Investor Answers

Baxter International Inc (NYSE-BAX) Stock FAQ

Quick answers about Baxter International Inc (NYSE-BAX) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$26.49
Estimated upside 20.1%
Valuation Rating
Undervalued
Estimated upside of 20.1%
Analyst Target
$21.95
Implied downside 0.5%
Financial Health
Good
Current financial-health read

The current fair value estimate for Baxter International Inc (NYSE-BAX) is $26.49. This implies an estimated upside of 20.1% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 20.1% versus the current market price.

The available analyst price target for Baxter International Inc (NYSE-BAX) is $21.95. The analyst target implies estimated downside of 0.5%.

The current financial health read for Baxter International Inc (NYSE-BAX) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Baxter International Inc (NYSE-BAX) is July 30, 2026.

Based on the current data, dividend yield is 0.2%, upcoming dividend amount is 0.04.

The current P/E ratio listed for Baxter International Inc (NYSE-BAX) is -11.6x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Baxter International Inc is 11.398 B.

The current enterprise value listed for Baxter International Inc is 19.031 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Baxter International Inc is NYSE-BAX, and the stock is listed on NYSE.

Baxter International Inc (NYSE-BAX) is listed on NYSE.

The current debt-to-total-capital ratio listed for Baxter International Inc is 46.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Baxter International Inc is 99.5%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks on NYSE View more

Abbott Laboratories (ABT) Abbott Laboratories (ABT)
Stryker Corporation (SYK) Stryker Corporation (SYK)
Medtronic PLC (MDT) Medtronic PLC (MDT)
Boston Scientific Corp (BSX) Boston Scientific Corp (BSX)
Edwards Lifesciences Corp (EW) Edwards Lifesciences Corp (EW)
Becton Dickinson and Co (BDX) Becton Dickinson and Co (BDX)
Alcon AG (ALC) Alcon AG (ALC)
ResMed Inc (RMD) ResMed Inc (RMD)
Koninklijke Philips NV ADR (PHG) Koninklijke Philips NV ADR (PHG)
STERIS plc (STE) STERIS plc (STE)
Zimmer Biomet Holdings Inc (ZBH) Zimmer Biomet Holdings Inc (ZBH)
Solventum Corp (SOLV) Solventum Corp (SOLV)
Smith & Nephew SNATS Inc (SNN) Smith & Nephew SNATS Inc (SNN)
Penumbra Inc (PEN) Penumbra Inc (PEN)
Globus Medical (GMED) Globus Medical (GMED)
Glaukos Corp (GKOS) Glaukos Corp (GKOS)
Teleflex Incorporated (TFX) Teleflex Incorporated (TFX)
Bausch + Lomb Corp (BLCO) Bausch + Lomb Corp (BLCO)
Envista Holdings Corp (NVST) Envista Holdings Corp (NVST)
Haemonetics Corporation (HAE) Haemonetics Corporation (HAE)
Integer Holdings Corp (ITGR) Integer Holdings Corp (ITGR)
Butterfly Network, Inc (BFLY) Butterfly Network, Inc (BFLY)
Enovis Corp (ENOV) Enovis Corp (ENOV)
Inspire Medical Systems Inc (INSP) Inspire Medical Systems Inc (INSP)